The chemotherapy of malignant disease in childhood, although only palliative, may be of great value in relieving distress, prolonging life and occasionally producing sufficient shrinkage of a tumour to enable surgical excision to be performed. Although a large number of compounds have been tested for anti-neoplastic activity only a few have found a useful place in therapy as most substances showing this activity have proved too toxic for clinical use. Our own experience has been limited to the use of some five or six drugs.
Malignant disease in children offers certain advantages in the assessment of chemotherapy. The patients are often in better general condition than adults with cancer, as their illness is not complicated by the presence of cardiovascular disease, chronic respiratory disease or renal insufficiency as is so often the case in the elderly. If there is a response to treatment it is often more clear-cut than in adults. Therapeutic enthusiasm, however, may be diminished by reluctance to cause further distress from toxic effects of treatment and by the technical difficulties of repeated intravenous infusions in young children.
Cyclophosphamide (Fairley & Simister 1964) : This is a compound of nitrogen mustard with a phosphoric acid ester. The action of phosphamidases, which are present in higher concentration in malignant than in normal tissues, liberates the active mustard fraction. We have used the drug (in dosage of 3 to 5 mg/kg/day) in about 25 patients with various forms of malignant disease including a few children in terminal relapse of leukemia. About half the patients had Hodgkin's disease and considerable regression of advanced disease has been observed in a few patients. Others with Stage I disease have received maintenance treatment following local radiotherapy. Four patients with neuroblastoma have shown temporary regression of tumour mass and skeletal metastases whilst on treatment.
The main toxic effects observed have been nausea and anorexia; alopecia, usually only slight; leucopenia, which was rarely severe and improved when the drug was discontinued for a few days; and mild chemical cystitis. Herpes zoster occurred in two girls under treatment for Hodgkin's disease (Keidan & Mainwaring 1965) .
Actinomycin D: This is one of a group of antibiotics obtained from a culture of streptomyces (Waksman &Woodruff 1940) . In 1956 Farber etal showed the actinomycin D had some inhibitory effect on a number of childhood tumours. Since 1960 we have treated about 30 patients with this drug. A single course of treatment was originally 75 pg per kg body weight but later this was increased to 120 pg per kg divided into 10 daily intravenous doses. Patients have received from 1 to 4 courses of treatment.
Over half the patients had Wilms's tumour. Nearly all had nephrectomy and most received post-operative irradiation in addition to chemotherapy but, owing to the increased hazard of combined treatment (although there is an increased therapeutic effect as well), more recently selected patients, who showed no evidence of gland involvement, have only had chemotherapy after operation and so far have done well although the period of follow-up is short (Keidan 1966) . A few patients with metastatic Wilms's tumour have shown a response to actinomycin D (with or without radiotherapy) and one child who had combined treatment for pulmonary metastases is alive and apparently free from disease four years later. Another child has had multiple recurrences and although he now has widespread metastases, he is free from symptoms four years after nephrectomy.
In other tumours there has been some relief of pain but little objective evidence of response. One child with multiple skin deposits from a synovial sarcoma showed considerable, but very brief, regression of the subcutaneous tumours.
Actinomycin D produces many toxic effects including stomatitis; nausea and vomiting; diarrhoea; erythema and necrosis of the skin; alopecia; pancytopenia; and hepatitis.
Vinblastine: This is an alkaloid derived from the Malagasy periwinkle (Vinca rosea) which is used mainly in the treatment of Hodgkin's disease, especially in patients who have become refractory to other drugs and are unsuitable for radiotherapy. The drug is given byintravenous injection once weekly. We have used it in treatment of a number of children and have observed considerable shrinkage of posterior abdominal lymph nodes with improvement in general health.
Its toxic effects include alimentary disturbances, alopecia and sensory and motor disturbances, of peripheral nerves.
Vincristine: Also derived from Vinca rosea, this alkaloid has a different range of activity from vinblastine and has been used mainly in the treatment of acute leukwmia. In solid tumours it has produced remarkable regression in a number of children with lymphosarcoma. Considerable improvement has also occurred in disseminated neuroblastoma. Regression of metastatic Wilms's tumour has also been reported (Sutow et al. 1963) but our own limited experience has so far been disappointing.
Toxic effects are common and may be severe. They include alopecia; severe constipation; stomatitis; and neurotoxicity especially involving the oculomotor nerves.
Methotrexate: This antagonist of folic acid has been used mainly in the treatment of acute leukemia. We have also used it by arterial infusion in the treatment of a rhabdomyosarcoma of the orbit. Treatment was given continuously for twenty-one days. There was considerable relief of pain and some shrinkage of the tumour but the improvement was very brief. We have also used methotrexate intravenously in treatment of a lymphosarcoma of the jaw and observed considerable shrinkage of the tumour.
Methyl hydrazine (Mathe et al. 1963) : We have used this synthetic drug in 3 children with disseminated Hodgkin's disease. Two showed considerable improvement both in size of lymph nodes and in systemic disturbance but one of these children died of severe marrow aplasia. The third child showed little or no response.
Mustine hydrochloride: This drug was recently used for arterial perfusion of a malignant sacrococcygeal tumour which was filling the pelvis and causing partial obstruction of bowel and bladder. There was remarkable shrinkage of the tumour mass and a few weeks later surgical excision was possible. Metastatic spread to the liver had already occurred however and the child died seven months later.
In summary, a useful degree of palliation has been produced in a few children with advanced malignant disease and occasionally there has been sustained improvement for a prolonged period. Much remains to be learned about the best ways of using the drugs we have at present both in the initial treatment of childhood cancer and in the management of advanced disease. Combined treatment with two or three drugs is already under trial but produces an increase of toxic effects almost to the limit of endurance and such treatment is hard to justify unless there is a real prospect of complete eradication of the disease. The doctor must be ready to admit defeat and allow the patient to die in comfort.
While we hopefully await the development of new drugs with enhanced activity and reduced toxicity, the present efforts are worth while as they offer some hope to the parents of these unhappy children and occasional unexpected improvements continue to give encouragement.
